{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:58:25Z","timestamp":1760266705470},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00415-006-5007-x","type":"journal-article","created":{"date-parts":[[2006,9,24]],"date-time":"2006-09-24T15:40:15Z","timestamp":1159112415000},"page":"v50-v58","source":"Crossref","is-referenced-by-count":16,"title":["Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis"],"prefix":"10.1007","volume":"253","author":[{"given":"Ales","family":"Dudesek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5007_CR1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archneur.1992.00530360031013","volume":"49","author":"Achiron","year":"1992","unstructured":"Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, Noy S, Sarova-Pinhas I, Melamed E (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting Multiple Sclerosis. Arch Neurol 49:1233\u20131236","journal-title":"Arch Neurol"},{"key":"5007_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","volume":"50","author":"Achiron","year":"1998","unstructured":"Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398\u2013402","journal-title":"Neurology"},{"key":"5007_CR3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, Achiron R (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133\u20131137","journal-title":"J Neurol"},{"key":"5007_CR4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","volume":"61","author":"Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515\u20131520","journal-title":"Arch Neurol"},{"key":"5007_CR5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/1352458500006001011","volume":"6","author":"Bieber","year":"2000","unstructured":"Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M (2000) Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler 6(Suppl 2):S1\u2013S5","journal-title":"Mult Scler"},{"key":"5007_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0022-510X(02)00069-2","volume":"206","author":"Bjartmar","year":"2003","unstructured":"Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165\u2013171","journal-title":"J Neurol Sci"},{"key":"5007_CR7","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"Comi","year":"2001","unstructured":"Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR. Early Treatment of Multiple Sclerosis Study Group (2001) Effect on early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576\u20131582","journal-title":"Lancet"},{"key":"5007_CR8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","volume":"49","author":"Comi","year":"2001","unstructured":"Comi G, Filippi M, Wolinsky JS (2001) European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European\/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290\u2013297","journal-title":"Ann Neurol"},{"key":"5007_CR9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/brain\/awg081","volume":"126","author":"Confavreux","year":"2003","unstructured":"Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770\u2013782","journal-title":"Brain"},{"key":"5007_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0404.1992.tb05061.x","volume":"86","author":"Cook","year":"1992","unstructured":"Cook SD, Troiano R, Rohowsky-Kochan C, Jotkowitz A, Bielory L, Mehta PD, Oleske J, Bansil S, Dowling PC (1992) Intravenous gamma globulin in progressive MS. Acta Neurol Scand 86:171\u2013175","journal-title":"Acta Neurol Scand"},{"key":"5007_CR11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O\u2019Brien PC (1994) A plasma exchange versus immune globuline infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838\u2013845","journal-title":"Ann Neurol"},{"key":"5007_CR12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","volume":"349","author":"Fazekas","year":"1997","unstructured":"Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis.Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589\u2013593","journal-title":"Lancet"},{"key":"5007_CR13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1191\/1352458505ms1224oa","volume":"11","author":"Haas","year":"2005","unstructured":"Haas J, Maas-Enriquez M, Hartung HP (2005) Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis\u2014results of a retrospective multicenter observational study over five years. Mult Scler 11:562\u2013567","journal-title":"Mult Scler"},{"key":"5007_CR14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","volume":"364","author":"Hommes","year":"2004","unstructured":"Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozilli C, O\u2019Connor P (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149\u20131156","journal-title":"Lancet"},{"key":"5007_CR15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","volume":"343","author":"Jacobs","year":"2000","unstructured":"Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 343:898\u2013904","journal-title":"N Engl J Med"},{"key":"5007_CR16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285\u2013294","journal-title":"Ann Neurol"},{"key":"5007_CR17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268\u20131276","journal-title":"Neurology"},{"key":"5007_CR18","first-page":"10","volume":"Scler","author":"Kappos","year":"2005","unstructured":"Kappos L, Polman C, Freedman MS, Edan GC, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Sandbrink R on behalf of the BENEFIT Study Group (2005) Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): clinical results. Mult Scler (Suppl 1):10","journal-title":"Mult"},{"key":"5007_CR19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","volume":"30","author":"Kieseier","year":"2004","unstructured":"Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131\u2013156","journal-title":"Muscle Nerve"},{"key":"5007_CR20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00234-003-1088-8","volume":"46","author":"Ko\u00e7er","year":"2004","unstructured":"Ko\u00e7er B, Yildirim-Gurel S, Tali ET, Irkec C, Isik S (2004) The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G. Neuroradiology 46:287\u2013290","journal-title":"Neuroradiology"},{"key":"5007_CR21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1468-1331.2002.00500.x","volume":"9","author":"Lewanska","year":"2002","unstructured":"Lewanska M, Siger-Zajdel M, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565\u2013572","journal-title":"Eur J Neurol"},{"key":"5007_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s001150050452","volume":"70","author":"MS-Therapie","year":"1999","unstructured":"MS-Therapie Konsensus Gruppe (1999) Immunomodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371\u2013386","journal-title":"Nervenarzt"},{"key":"5007_CR23","first-page":"150","volume":"72","author":"MS-Therapie","year":"2000","unstructured":"MS-Therapie Konsensus Gruppe (2000) Immunomodulatorische Stufentherapie der multiplen Sklerose. I. Erg\u00e4nzung.Nervenarzt 72:150\u2013157","journal-title":"Nervenarzt"},{"key":"5007_CR24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00115-002-1328-x","volume":"73","author":"MS-Therapie","year":"2002","unstructured":"MS-Therapie Konsensus Gruppe (2002) Immunmodulatorische Stupentherapie der multiplen Sklerose. Neue Aspekte und praktische Umsetzung. Nervenarzt 73:556\u2013563","journal-title":"Nervenarzt"},{"key":"5007_CR25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00415-004-0537-6","volume":"251","author":"Multiple","year":"2004","unstructured":"Multiple Sclerosis Therapy Consensus Group (2004) Escalating immunotherapy of multiple sclerosis. J Neurol 251:1329\u20131339","journal-title":"J Neurol"},{"key":"5007_CR26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/brain\/124.7.1403","volume":"124","author":"Murray","year":"2001","unstructured":"Murray PD, McGavern DB, Sathornsumetee S, Rodriguez M (2001) Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. Brain 124:1403\u20131416","journal-title":"Brain"},{"key":"5007_CR27","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","volume":"56","author":"Noseworthy","year":"2001","unstructured":"Noseworthy JH, O\u2019Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514\u20131522","journal-title":"Neurology"},{"key":"5007_CR28","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","volume":"55","author":"Noseworthy","year":"2000","unstructured":"Noseworthy JH, O\u2019Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM Jr, Low PA, Romme LJ, Johnson M, An KN, Rodriguez M (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55:1135\u20131143","journal-title":"Neurology"},{"key":"5007_CR29a","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/135245859700300217","volume":"3","author":"P\u00f6hlau","year":"1997","unstructured":"P\u00f6hlau D, Federlein J, Postert T, Sailer M, Bethke F, Kappos L, Haas J, Przuntek H (1997) Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis\u2014outline of a double-blind randomized, placebo-controlled trial. Mult Scler 3:149\u2013152","journal-title":"Mult Scler"},{"key":"5007_CR29b","first-page":"163","volume":"Scler","author":"P","year":"2005","unstructured":"P\u00f6hlau D, Przuntek H, Sp\u00e4th P, Andresen I and the IVIG Study Group (2005) Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosis. Mult Scler (Suppl 1):163","journal-title":"Mult"},{"key":"5007_CR30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"PRISMS","year":"1998","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352:1498\u20131504","journal-title":"Lancet"},{"key":"5007_CR31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.1255","volume":"50","author":"Prineas","year":"2001","unstructured":"Prineas JW, Kwon EE, Cho E, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP (2001) Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50:646\u2013657","journal-title":"Ann Neurol"},{"key":"5007_CR32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.410270104","volume":"27","author":"Rodriguez","year":"1990","unstructured":"Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27:12\u201317","journal-title":"Ann Neurol"},{"key":"5007_CR33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1212\/WNL.46.2.538","volume":"46","author":"Rodriguez","year":"1996","unstructured":"Rodriguez M, Miller DJ, Lennon VA (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46:538\u2013545","journal-title":"Neurology"},{"key":"5007_CR34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","volume":"64","author":"Roed","year":"2005","unstructured":"Roed HG, Langkilde A, Sellebjerg FT, Lauritzen M, Bang P, Morup A, Frederiksen JL (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64:804\u2013810","journal-title":"Neurology"},{"key":"5007_CR35","first-page":"74","volume":"124","author":"Rothfelder","year":"1982","unstructured":"Rothfelder U, Neu I, Pelka R (1982) Therapy of multiple sclerosis with immunoglobulin G MMW Munch Med Wochenschr 124:74\u201378","journal-title":"G MMW Munch Med Wochenschr"},{"key":"5007_CR36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000115560","volume":"22","author":"Schuller","year":"1983","unstructured":"Schuller E, Govaerts A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 22:205\u2013212","journal-title":"Eur Neurol"},{"key":"5007_CR37","doi-asserted-by":"crossref","first-page":"S861","DOI":"10.1007\/s100720070027","volume":"21","author":"Simone","year":"2000","unstructured":"Simone IL, Carrara D, Tortorella C, Ceccarelli A, Livrea P (2000) Early onset multiple sclerosis. Neurol Sci 21(4 Suppl 2):S861\u2013S863","journal-title":"Neurol Sci"},{"key":"5007_CR38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","volume":"50","author":"Sorensen","year":"1998","unstructured":"Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen V, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273\u20131281","journal-title":"Neurology"},{"key":"5007_CR39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","volume":"9","author":"Sorensen","year":"2002","unstructured":"Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557\u2013563","journal-title":"Eur J Neurol"},{"key":"5007_CR40","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","volume":"63","author":"Sorensen","year":"2004","unstructured":"Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group (2004) IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63:2028\u20132033","journal-title":"Neurology"},{"key":"5007_CR41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jnnp.68.1.89","volume":"68","author":"Stangel","year":"2000","unstructured":"Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89\u201392","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5007_CR42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00115-004-1733-4","volume":"75","author":"Stangel","year":"2004","unstructured":"Stangel M, Gold R (2004) Use of IV immunoglobulins in neurology. Evidence-based consensus. Nervenarzt 75:801\u2013815","journal-title":"Nervenarzt"},{"key":"5007_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp.72.1.1","volume":"72","author":"Stangel","year":"2002","unstructured":"Stangel M, Hartung HP (2002) Despair of repair. J Neurol Neurosurg Psychiatry 72:1\u20134","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5007_CR44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s002340000444","volume":"42","author":"Teksam","year":"2000","unstructured":"Teksam M, Tali T, Kocer B, Isik S (2000) Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 42:885\u2013889","journal-title":"Neuroradiology"},{"key":"5007_CR45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655\u2013661","journal-title":"Neurology"},{"key":"5007_CR46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278\u2013285","journal-title":"N Engl J Med"},{"key":"5007_CR47","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"van der Meche","year":"1992","unstructured":"van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123\u20131129","journal-title":"N Engl J Med"},{"key":"5007_CR48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1991.00530140113024","volume":"48","author":"van Doorn","year":"1991","unstructured":"van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neur 48:217\u2013220","journal-title":"Arch Neur"},{"key":"5007_CR49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","volume":"56","author":"Vermeulen","year":"1993","unstructured":"Vermeulen M, Van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36\u201339","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5007_CR50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"Visser","year":"2004","unstructured":"Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) A randomized, double-blind, placebo-controlled pilot study of i. v. immune globulins in combination i.v methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10:89\u201391","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-5007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-006-5007-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-5007-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:08:07Z","timestamp":1559056087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-006-5007-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":51,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["5007"],"URL":"https:\/\/doi.org\/10.1007\/s00415-006-5007-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}